242 related articles for article (PubMed ID: 24082123)
1. CRL4A-FBXW5-mediated degradation of DLC1 Rho GTPase-activating protein tumor suppressor promotes non-small cell lung cancer cell growth.
Kim TY; Jackson S; Xiong Y; Whitsett TG; Lobello JR; Weiss GJ; Tran NL; Bang YJ; Der CJ
Proc Natl Acad Sci U S A; 2013 Oct; 110(42):16868-73. PubMed ID: 24082123
[TBL] [Abstract][Full Text] [Related]
2. DLC1 interaction with S100A10 mediates inhibition of in vitro cell invasion and tumorigenicity of lung cancer cells through a RhoGAP-independent mechanism.
Yang X; Popescu NC; Zimonjic DB
Cancer Res; 2011 Apr; 71(8):2916-25. PubMed ID: 21372205
[TBL] [Abstract][Full Text] [Related]
3. Functional interaction of tumor suppressor DLC1 and caveolin-1 in cancer cells.
Du X; Qian X; Papageorge A; Schetter AJ; Vass WC; Liu X; Braverman R; Robles AI; Lowy DR
Cancer Res; 2012 Sep; 72(17):4405-16. PubMed ID: 22693251
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin negatively regulates neoplastic growth in non-small cell lung cancer: role of Rho GTPases.
Asnaghi L; Vass WC; Quadri R; Day PM; Qian X; Braverman R; Papageorge AG; Lowy DR
Oncogene; 2010 May; 29(19):2760-71. PubMed ID: 20228844
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of cytoplasmic EZH2 induces antitumor activity through stabilization of the DLC1 tumor suppressor protein.
Tripathi BK; Anderman MF; Bhargava D; Boccuzzi L; Qian X; Wang D; Durkin ME; Papageorge AG; de Miguel FJ; Politi K; Walters KJ; Doroshow JH; Lowy DR
Nat Commun; 2021 Dec; 12(1):6941. PubMed ID: 34862367
[TBL] [Abstract][Full Text] [Related]
6. The role of Dlc1 isoform 2 in K-Ras2(G12D) induced thymic cancer.
Sabbir MG; Prieditis H; Ravinsky E; Mowat MR
PLoS One; 2012; 7(7):e40302. PubMed ID: 22792269
[TBL] [Abstract][Full Text] [Related]
7. Cancer-Associated Point Mutations in the
Wang D; Qian X; Sanchez-Solana B; Tripathi BK; Durkin ME; Lowy DR
Cancer Res; 2020 Sep; 80(17):3568-3579. PubMed ID: 32606003
[TBL] [Abstract][Full Text] [Related]
8. Receptor tyrosine kinase activation of RhoA is mediated by AKT phosphorylation of DLC1.
Tripathi BK; Grant T; Qian X; Zhou M; Mertins P; Wang D; Papageorge AG; Tarasov SG; Hunter KW; Carr SA; Lowy DR
J Cell Biol; 2017 Dec; 216(12):4255-4270. PubMed ID: 29114068
[TBL] [Abstract][Full Text] [Related]
9. Fbxw5 suppresses nuclear c-Myb activity via DDB1-Cul4-Rbx1 ligase-mediated sumoylation.
Kanei-Ishii C; Nomura T; Egoh A; Ishii S
Biochem Biophys Res Commun; 2012 Sep; 426(1):59-64. PubMed ID: 22910413
[TBL] [Abstract][Full Text] [Related]
10. DLC1 induces expression of E-cadherin in prostate cancer cells through Rho pathway and suppresses invasion.
Tripathi V; Popescu NC; Zimonjic DB
Oncogene; 2014 Feb; 33(6):724-33. PubMed ID: 23376848
[TBL] [Abstract][Full Text] [Related]
11. DLC-1 tumor suppressor regulates CD105 expression on human non-small cell lung carcinoma cells through inhibiting TGF-β1 signaling.
Zhang K; Na T; Ge F; Yuan BZ
Exp Cell Res; 2020 Jan; 386(2):111732. PubMed ID: 31770531
[TBL] [Abstract][Full Text] [Related]
12. Ursodeoxycholic acid-induced inhibition of DLC1 protein degradation leads to suppression of hepatocellular carcinoma cell growth.
Chung GE; Yoon JH; Lee JH; Kim HY; Myung SJ; Yu SJ; Lee SH; Lee SM; Kim YJ; Lee HS
Oncol Rep; 2011 Jun; 25(6):1739-46. PubMed ID: 21455586
[TBL] [Abstract][Full Text] [Related]
13. EZH2-Mediated H3K27me3 Is Involved in Epigenetic Repression of Deleted in Liver Cancer 1 in Human Cancers.
Au SL; Wong CC; Lee JM; Wong CM; Ng IO
PLoS One; 2013; 8(6):e68226. PubMed ID: 23826380
[TBL] [Abstract][Full Text] [Related]
14. Morphological changes and nuclear translocation of DLC1 tumor suppressor protein precede apoptosis in human non-small cell lung carcinoma cells.
Yuan BZ; Jefferson AM; Millecchia L; Popescu NC; Reynolds SH
Exp Cell Res; 2007 Nov; 313(18):3868-80. PubMed ID: 17888903
[TBL] [Abstract][Full Text] [Related]
15. Full activity of the deleted in liver cancer 1 (DLC1) tumor suppressor depends on an LD-like motif that binds talin and focal adhesion kinase (FAK).
Li G; Du X; Vass WC; Papageorge AG; Lowy DR; Qian X
Proc Natl Acad Sci U S A; 2011 Oct; 108(41):17129-34. PubMed ID: 21969587
[TBL] [Abstract][Full Text] [Related]
16. High expression of DLC family proteins predicts better prognosis and inhibits tumor progression in NSCLC.
Sun L; Sun J; Song JD
Mol Med Rep; 2019 Jun; 19(6):4881-4889. PubMed ID: 31059015
[TBL] [Abstract][Full Text] [Related]
17. DLC1 SAM domain-binding peptides inhibit cancer cell growth and migration by inactivating RhoA.
Joshi R; Qin L; Cao X; Zhong S; Voss C; Min W; Li SSC
J Biol Chem; 2020 Jan; 295(2):645-656. PubMed ID: 31806702
[TBL] [Abstract][Full Text] [Related]
18. The tumor suppressor protein DLC1 maintains protein kinase D activity and Golgi secretory function.
Jensch A; Frey Y; Bitschar K; Weber P; Schmid S; Hausser A; Olayioye MA; Radde NE
J Biol Chem; 2018 Sep; 293(37):14407-14416. PubMed ID: 30045871
[TBL] [Abstract][Full Text] [Related]
19. Tumor suppressor gene DLC1: Its modifications, interactive molecules, and potential prospects for clinical cancer application.
Ren G; Li G
Int J Biol Macromol; 2021 Jul; 182():264-275. PubMed ID: 33836193
[TBL] [Abstract][Full Text] [Related]
20. DLC1 tumor suppressor gene inhibits migration and invasion of multiple myeloma cells through RhoA GTPase pathway.
Ullmannova-Benson V; Guan M; Zhou X; Tripathi V; Yang XY; Zimonjic DB; Popescu NC
Leukemia; 2009 Feb; 23(2):383-90. PubMed ID: 18923442
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
